NTLA Intellia Therapeutics, Inc.: institutional ownership and insider trading
348 funds reported holding $2.63B of Intellia Therapeutics, Inc. in their latest 13F filings; in Q2 2026 funds net bought $547M, with 50 new positions and 28 funds selling out; over the last 12 months insiders bought $1.40M and sold $2.16M on the open market.
Famous investors holding NTLA
- Cathie Wood (ARK Investment Management): $286M, 1.9% of the portfolio
- Two Sigma (Two Sigma Investments): $88.6M, 0.1% of the portfolio
- D. E. Shaw (D. E. Shaw & Co.): $109M, 0.1% of the portfolio
- Renaissance Technologies (Renaissance Technologies): $23.7M, 0.0% of the portfolio
- Ken Griffin (Citadel Advisors): $13.3M, 0.0% of the portfolio
- Izzy Englander (Millennium Management): $8.31M, 0.0% of the portfolio
Largest institutional holders of NTLA
- ARK Investment Management LLC — $286M
- BlackRock, Inc. (BLK) — $261M
- STATE STREET CORP (STT, STT-PG) — $156M
- VANGUARD PORTFOLIO MANAGEMENT LLC — $124M
- VANGUARD GROUP INC — $117M
- D. E. Shaw & Co., Inc. — $109M
- VANGUARD CAPITAL MANAGEMENT LLC — $102M
- TWO SIGMA INVESTMENTS, LP — $88.6M
- FMR LLC — $80.8M
- RA CAPITAL MANAGEMENT, L.P. — $76.6M
Recent NTLA insider trades
- Oct 2, 2026: Dube Michael P sold 1,864 shares ($23.2K)
- Aug 21, 2026: Leonard John M sold 22,675 shares ($287K)
- Jul 22, 2026: Dulac Edward J III sold 8,111 shares ($91.2K)
- Jul 2, 2026: Dulac Edward J III sold 4,677 shares ($84.2K)
5%+ owners
- STATE STREET CORPORATION: 6.8% (Schedule 13G, filed Aug 7, 2026)
- Vanguard Portfolio Management: 5.3% (Schedule 13G, filed Apr 29, 2026)
- Vanguard Capital Management: 5.0% (Schedule 13G, filed Apr 30, 2026)